Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM512 injection in moderate-to-severe atopic dermatitis – long-term open-label study
CTR20254545Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Nov 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CM512 in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started Nov 2025; status: active.
02
Drugs
CM512
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20254545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254545.